Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. (Q52957346)

9 May 2018

title

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. (English)

1 reference

9 May 2018

Primary systemic amyloidosis

main subject

1 reference

Mollee PN

1

1 reference

9 May 2018

Wechalekar AD

2

1 reference

9 May 2018

Pereira DL

3

1 reference

9 May 2018

Franke N

4

1 reference

9 May 2018

Reece D

5

1 reference

9 May 2018

Chen C

6

1 reference

9 May 2018

Stewart AK

7

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 May 2018

Bone Marrow Transplantation

published in

1 reference

9 May 2018

volume

33

1 reference

9 May 2018

issue

3

1 reference

9 May 2018

page(s)

271-277

1 reference

9 May 2018

Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

21 January 2018

The systemic amyloidoses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

7 January 2021

Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

7 January 2021

Characterization of the phosphatidylserine-exposing subpopulation of sickle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

7 January 2021

High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

7 January 2021

High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

7 January 2021

Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704344

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704344

1 reference

9 May 2018

1 reference

9 May 2018